In addition, in a cardiovascular outcome study involving patients with type 2 diabetes, of whom more than 80% had a history of cardiovascular disease, semaglutide treatment lowered the rates of 3-point MACE (myocardial infarction, stroke and cardiovascular death) [31]
This aspect of personalized geroscience could improve treatment outcomes, tailoring therapeutic approaches to an individuals distinct organ aging characteristics in addition to their chronological age
Major trials did not identify anxiety as a primary safety concern, but real-world reports and neurobiological mechanisms suggest susceptible individuals may experience mood shifts during treatment initiation
Liraglutide and semaglutide are both GLP-1 agonists, medications capable of helping patients with weight loss, but they differ in their dosing schedule and overall effectiveness
I will help you with all of these and I save you time your most valuable asset